VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MRNA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MRNAModerna, Inc.
$206.80$82.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksMRNABalance Sheet

Moderna, Inc. (MRNA) Balance Sheet

10Y historyFree accessUpdated daily

Total debt jumped from $1.3B to $4.2B within Q3 2026 and the debt-to-equity ratio rose from 0.19 to 0.61, while equity contracted from $11.9B in 2024Q3 to $6.8B, indicating a more leveraged and shrinking capital base.

Income StatementBalance SheetCash FlowRatios

MRNA Balance Sheet

Annual statement

MRNA Balance Sheet

Moderna, Inc. (MRNA) balance sheet — 10-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Total Current Assets7.34B6.54B8.1B10.32B13.43B16.07B6.3B1.13B1.56B783.22M1.09B
Cash & Short-Term Investments5.17B5.8B7.03B8.6B9.9B10.73B4.61B1.1B1.52B756.03M1.06B
Cash Only1.2B2.6B1.93B2.91B3.21B6.85B2.62B235.88M658.36M134.86M50.08M
Short-Term Investments3.98B3.2B5.1B5.7B6.7B3.88B1.98B867.12M863.06M621.17M1.01B
Accounts Receivable1.37B284M592M1.08B1.69B3.32B1.41B16.3M30.58M18.4M17.95M
Days Sales Outstanding68.753.3267.5557.6232.5868.39639.6998.882.6532.6460.45
Inventory313M153M117M202M949M1.44B47M0000
Days Inventory Outstanding44.7764.3429.1715.7163.96200.98437.81----
Other Current Assets493M45M58M88M44M26M11M1.03M595K951K0
Total Non-Current Assets6.12B5.79B6.04B8.1B12.43B8.6B1.04B460.62M399.14M301.27M330.01M
Property, Plant & Equipment2.72B2.85B2.96B2.66B2.14B1.38B387M287.91M211.98M139.03M81.21M
Fixed Asset Turnover0.91x0.68x1.08x2.58x8.82x12.82x2.08x0.21x0.64x1.48x1.33x
Goodwill052M52M52M0000000
Intangible Assets045M40M44M0000000
Long-Term Investments9.49B2.34B2.51B4.74B8.36B6.84B639M159.99M172.99M145.85M236.57M
Other Non-Current Assets596M421M407M523M946M46M13M12.72M14.18M16.38M12.23M
Total Assets13.47B12.34B14.14B18.43B25.86B24.67B7.34B1.59B1.96B1.08B1.42B
Asset Turnover0.21x0.16x0.23x0.37x0.73x0.72x0.11x0.04x0.07x0.19x0.08x
Asset Growth %-20.08%-12.76%-23.25%-28.74%4.82%236.23%361.61%-19%80.93%-23.47%-
Total Current Liabilities2.03B1.99B2.21B3.02B4.92B9.13B4.39B143.12M222.8M191.46M162.8M
Accounts Payable259M317M405M520M487M302M18M7.09M31.21M20.73M28.16M
Days Payables Outstanding45.37133.3100.9740.4432.8242.12167.6783.42458.2368.34679.99
Short-Term Debt00000000000
Deferred Revenue (Current)764M99M153M568M2.04B6.25B3.87B63.31M109.06M96.74M107.74M
Other Current Liabilities106M1.57B863M842M243M140M99M32.49M26.87M19.5M13.54M
Current Ratio3.62x3.29x3.67x3.42x2.73x1.76x1.43x7.89x7.02x4.09x6.68x
Quick Ratio3.47x3.22x3.62x3.36x2.54x1.60x1.42x7.89x7.02x4.09x6.68x
Cash Conversion Cycle68.1-15.64-4.2632.8863.72227.25909.82----
Total Non-Current Liabilities4.6B1.7B1.03B1.56B1.81B1.4B387M271.5M209.1M267.73M412.51M
Long-Term Debt3.55B1.24B000000000
Capital Lease Obligations2.6B673M710M1.22B1B705M207M132.36M33.49M15.69M12.5M
Deferred Tax Liabilities508M0000000000
Other Non-Current Liabilities285M-368M267M256M135M76M3M138K10.26M9.12M5.76M
Total Liabilities6.63B3.69B3.24B4.57B6.74B10.52B4.78B414.61M431.91M459.19M575.31M
Total Debt4.18B1.92B747M1.24B1.2B916M237M132.36M33.49M15.69M12.5M
Net Debt2.98B-679M-1.18B-1.66B-2B-5.93B-2.39B-103.51M-624.88M-119.17M-37.58M
Debt / Equity0.61x0.22x0.07x0.09x0.06x0.06x0.09x0.11x0.02x0.03x0.01x
Debt / EBITDA-1.56x---0.12x0.07x-----
Net Debt / EBITDA-1.12x----0.21x-0.44x-----
Interest Coverage-108.48x-276.80x-149.29x-102.74x331.17x739.06x-74.31x-76.85x-141.12x-1938.36x-
Total Equity6.84B8.65B10.9B13.85B19.12B14.14B2.56B1.17B1.53B625.3M841.85M
Equity Growth %-101.84%-20.65%-21.32%-27.55%35.19%452.32%117.99%-23.23%144.72%-25.72%-
Book Value per Share15.9022.2428.3936.2745.9732.826.723.554.651.6613.13
Total Shareholders' Equity6.84B8.65B10.9B13.85B19.12B14.14B2.56B1.17B1.53B625.3M841.85M
Common Stock000000034K33K6K6K
Retained Earnings5.26B7.22B10.04B13.61B18.32B9.96B-2.24B-1.5B-1.01B-621.89M-365.72M
Treasury Stock00000000000
Accumulated OCI8M45M-10M-123M-370M-24M3M1.8M-1.32M-1.16M-403K
Minority Interest00000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Cash reserves declining against burn

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Balance Sheet Shrinking From Pandemic Peak

Based on reported figures, Moderna's total assets fell from $15.8B in 2024Q3 to $11.0B in 2026Q2 before recovering to $13.5B in 2026Q3, while equity contracted from $11.9B to $6.8B, indicating the balance sheet has been consumed by operating losses rather than rebuilt by earnings.

The decline in equity from roughly $11.9B to $6.8B is largely explained by accumulated losses reducing retained earnings from $11.2B to $5.3B over the period shown. The Q3 2026 rebound in total assets appears driven by a rise in liabilities and debt rather than retained profitability, which suggests the recovery should be read cautiously. Investors should monitor whether the asset base can be sustained without further dilution of the equity cushion.

Debt Rising Sharply Into Quarter-End

According to reported balance sheet data, total debt rose from $1.3B in 2026Q2 to $4.2B in 2026Q3, lifting the debt-to-equity ratio from 0.19 to 0.61 within a single quarter and marking the highest leverage in the ten-quarter window.

The jump in debt appears to be a deliberate financing decision rather than an operating necessity, given that cash was $1.2B at quarter end and had been higher previously. Leverage remains moderate in absolute terms but is rising against a shrinking equity base. The refinancing profile and maturity schedule are not disclosed in the supplied data, so the durability of this debt load warrants further investigation.

Cash Cushion Thinning Against Burn

As reported in financial statements, Moderna's cash position declined from $2.6B in 2025Q4 to $1.2B in 2026Q3, while the current ratio of 3.62 remains comfortable on paper, though the cash runway implied by the negative free cash flow margin of -122.3% appears limited.

A current ratio above 3 suggests short-term obligations are covered, yet this is largely a function of current assets that may include inventory and receivables rather than readily deployable cash. Cash has fallen by more than half over three quarters while the company continues to burn capital. This pattern suggests the buffer against commercial or regulatory shocks has narrowed materially.

Fixed Asset Base Stable, Goodwill Minimal

Based on Moderna's reported figures, net PP&E has held in a narrow band of roughly $2.7B to $3.2B across the period, while goodwill is only $52M, indicating impairment risk on the balance sheet is low even as the manufacturing footprint remains heavy.

The stable PP&E figure combined with the historically high fixed-cost manufacturing base suggests the asset-heavy model has not been scaled down in line with post-pandemic demand. Low goodwill means the balance sheet is not inflated by acquisition accounting, making tangible asset values a more direct read on capital employed. The risk here is less about write-offs of intangibles and more about whether the productive capacity can earn an adequate return.

Q3 Rebound Masks Structural Leverage Shift

Headline improvement in the Q3 2026 balance sheet may mislead, as total assets recovered to $13.5B while debt more than tripled from $1.3B and equity stayed near $6.8B, suggesting the apparent strength is financed rather than earned.

The most non-obvious distortion is that the asset recovery coincides with a sharp increase in debt and a falling retained earnings balance, so the headline asset figure does not reflect improved solvency. The deferred revenue swing from $442M to $407M and the current ratio fluctuations also show that working capital metrics are sensitive to timing of collections and milestone recognition. Based on reported figures, the quarter's positive earnings surprise has not yet translated into a stronger equity base, so this interpretation should be weighed against the sustained negative trailing margins.

MRNA — Frequently Asked Questions

Quick answers to the most common questions about buying MRNA stock.

What are the total assets of Moderna, Inc. (MRNA)?

As of 2025, Moderna, Inc. (MRNA) had total assets of $12.34B including $6.54B in current assets.

How much debt does Moderna, Inc. (MRNA) have?

Moderna, Inc. (MRNA) carries total debt of $1.92B, offset by $5.80B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Moderna, Inc.?

Moderna, Inc. (MRNA) has total shareholders' equity (book value) of $8.65B ($22.24 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Moderna, Inc.'s current ratio and liquidity?

Moderna, Inc. (MRNA) reported a current ratio of 3.29x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.